Rivaroxaban to prevent clinical outcomes in covid 19 patients: MICHELLE TRIAL

Covid-19 also known SARS Cov-2 is popularly known to cause more fatal events where severe respiratory problems and multi organ failure in the infected top the adverse effect. Most people infected with the virus present with mild to moderate respiratory illness and recover without requiring special treatment. Being declared as a global pandemic several measures have been taken to handle the virus, newer drugs are been found and investigated to defeat the pandemic.

However, some become seriously ill and require medical attention. Older people and those with underlying medical conditions like cardiovascular disease, diabetes, chronic respiratory disease, or cancer are more likely to develop serious illness. Anyone can get sick with COVID-19 and become seriously ill or die at any age. Rivaroxaban is used popularly to treat and prevent deep venous thrombosis (DVT), a condition in which harmful blood clots form in the blood vessels of the legs.

The MICHELLE trial reveals that rivaroxaban after hospitalization for COVID-19 improved clinical outcomes without increasing bleeding. The trials main purpose was to evaluate rivaroxaban compared with control among patients discharged after hospitalization for coronavirus disease infection. Trial findings are published in journal American College of Cardiology.

Over 160 participants discharged after COVID-19 infection were randomized to rivaroxaban 10 mg daily, vs control.The primary outcome, reported symptomatic venous thromboembolism(VTE), venous thromboembolism-related death, bilateral venous thromboembolism, symptomatic arterial thromboembolism, myocardial infarction, nonhemorrhagic stroke, major adverse limb event, or cardiovascular death at 35 days, was 3.14% in the rivaroxaban group compared with 9.43% in the control group. Incidence of major bleeding according to International Society on Thrombosis and Haemostasis (ISTH) criteria: 0% vs. 0%

Trial concluded that Among patients discharged after COVID-19 infection, rivaroxaban for 35 days was beneficial. Rivaroxaban was associated with a reduction in clinical events without increasing major bleeding.

Reference: https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2021/08/26/01/11/Michelle